Immunohistochemical Evaluation of COL11A1 and FGD3 Expression in Invasive Breast Cancer
Main Article Content
Abstract
Background: Collagen type XI, alpha 1 (COL11A1) is a minor component of extracellular matrix and its overexpression is associated with tumoral progression and poorer outcome in several human cancers; data on breast cancer are promising but scarce. FGD3 expression has been shown to be a strong independent prognostic factor in breast cancer. The aim of our study was to investigate whether COL11A1 expression correlates with other classic pathologic prognostic factors including FGD3 expression, as well as with clinical outcome, to evaluate its potential use as prognostic factor in breast cancer patients.
Methods: We evaluated by immunohistochemistry COL11A1 expression and we studied the relationship between this protein expression and traditional breast cancer prognostic factors, FGD3 expression, as well as with patients’ outcome.
Results: We found that higher stromal COL11A1 expression was associated with higher tumour grade (G3) (p = 0.001), higher Ki67 proliferation index (p = 0.006), more advanced AJCC stage (p = 0.031) and lower FGD3 expression (p = 0.039). In a case-control analysis, we observed that patients with high-COL11A1 had a higher risk of recurrence (OR = 2.0) and of dying of the disease (OR = 2.0). Patients with high-COL11A1-expressing tumours had shorter disease-free survival and overall survival (difference not significant). There was a linear positive correlation between COL11A1 expression on epithelial tumoral cells and surrounding stromal cells (r = 0.247, p = 0.04).
Conclusion: Our findings suggest that COL11A1 may represent a marker of aggressiveness in invasive breast cancer and that its detection warrants further study on larger series to evaluate its possible use in clinical practice.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Sparano JA, Gray RJ, Makower DF, et al. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med. 2015;373(21):2005-14. doi: 10.1056/NEJMoa1510764. PMID: 26412349
3. Cardoso F, van't Veer LJ, Bogaerts J, et al. MINDACT Investigators. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med. 2016;375(8):717-29. doi: 10.1056/NEJMoa1602253. PMID: 27557300.
4. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-74. doi: 10.1016/j.cell.2011.02.013. PMID: 21376230.
5. Kivirikko KI. Biosynthesis of collagen and its disorders. Duodecim. 1977;93(17):1070-89. PMID: 340198.
6. Bernard M, Yoshioka H, Rodriguez E, et al. Cloning and sequencing of pro-alpha 1 (XI) collagen cDNA demonstrates that type XI belongs to the fibrillar class of collagens and reveals that the expression of the gene is not restricted to cartilagenous tissue. J Biol Chem. 1988;263(32):17159-66. PMID: 3182841.
7. Shen L, Yang M, Lin Q, Zhang Z, Zhu B, Miao C. COL11A1 is overexpressed in recurrent non-small cell lung cancer and promotes cell proliferation, migration, invasion and drug resistance. Oncol Rep. 2016;36(2):877-85. doi: 10.3892/or.2016.4869. PMID: 27373316.
8. Wu YH, Chang TH, Huang YF, Huang HD, Chou CY. COL11A1 promotes tumor progression and predicts poor clinical outcome in ovarian cancer. Oncogene. 2014;33(26):3432-40. doi: 10.1038/onc.2013.307. PMID: 23934190.
9. Sok JC, Lee JA, Dasari S, et al. Collagen type XI α1 facilitates head and neck squamous cell cancer growth and invasion. Br J Cancer. 2013;109(12):3049-56. doi: 10.1038/bjc.2013.624. PMID: 24231953
10. Erkan M, Weis N, Pan Z, et al. Organ-, inflammation- and cancer specific transcriptional fingerprints of pancreatic and hepatic stellate cells. Mol Cancer. 2010;9:88. doi: 10.1186/1476-4598-9-88. PMID: 20416094
11. Zhao Y, Zhou T, Li A, et al. A potential role of collagens expression in distinguishing between premalignant and malignant lesions in stomach. Anat Rec (Hoboken). 2009;292(5):692-700. doi: 10.1002/ar.20874. PMID: 19306436.
12. Fischer H, Stenling R, Rubio C, Lindblom A. Colorectal carcinogenesis is associated with stromal expression of COL11A1 and COL5A2. Carcinogenesis. 2001;22(6):875-8. doi: 10.1093/carcin/22.6.875. PMID: 11375892.
13. Kleman JP, Hartmann DJ, Ramirez F, van der Rest M. The human rhabdomyosarcoma cell line A204 lays down a highly insoluble matrix composed mainly of alpha 1 type-XI and alpha 2 type-V collagen chains. Eur J Biochem. 1992;210(1):329-35. doi: 10.1111/j.1432-1033.1992.tb17425.x. PMID: 1446681.
14. Zhu K, Cai L, Cui C, de Los Toyos JR, Anastassiou D. Single-cell analysis reveals the pan-cancer invasiveness-associated transition of adipose-derived stromal cells into COL11A1-expressing cancer-associated fibroblasts. PLoS Comput Biol. 2021;17(7):e1009228. doi: 10.1371/journal.pcbi.1009228. PMID: 34283835
15. Gu SQ, Luo JH, Yao WX. The regulation of miR-139-5p on the biological characteristics of breast cancer cells by targeting COL11A1. Math Biosci Eng. 2019;17(2):1428-1441. doi: 10.3934/mbe.2020073. PMID: 32233587.
16. Ellsworth RE, Seebach J, Field LA, et al. A gene expression signature that defines breast cancer metastases. Clin Exp Metastasis. 2009;26(3):205-13. doi: 10.1007/s10585-008-9232-9. PMID: 19112599.
17. Willis S, Sun Y, Abramovitz M, et al. High Expression of FGD3, a Putative Regulator of Cell Morphology and Motility, Is Prognostic of Favorable Outcome in Multiple Cancers. JCO Precis Oncol. 2017;1:PO.17.00009. doi: 10.1200/PO.17.00009. PMID: 32913979
18. Freire J, Domínguez-Hormaetxe S, Pereda S, et al. Collagen, type XI, alpha 1: an accurate marker for differential diagnosis of breast carcinoma invasiveness in core needle biopsies. Pathol Res Pract. 2014;210(12):879-84. doi: 10.1016/j.prp.2014.07.012. PMID: 25175819.
19. Freire J, García-Berbel L, García-Berbel P, et al. Collagen Type XI Alpha 1 Expression in Intraductal Papillomas Predicts Malignant Recurrence. Biomed Res Int. 2015;2015:812027. doi: 10.1155/2015/812027. PMID: 26448946
20. Vargas AC, McCart Reed AE, Waddell N, et al. Gene expression profiling of tumour epithelial and stromal compartments during breast cancer progression. Breast Cancer Res Treat. 2012;135(1):153-65. doi: 10.1007/s10549-012-2123-4. PMID: 22718308.
21. Toss MS, Miligy IM, Gorringe KL, et al. Collagen (XI) alpha-1 chain is an independent prognostic factor in breast ductal carcinoma in situ. Mod Pathol. 2019;32(10):1460-1472. doi: 10.1038/s41379-019-0286-9. PMID: 31175327.
22. Luo Q, Li J, Su X, Tan Q, Zhou F, Xie S. COL11A1 serves as a biomarker for poor prognosis and correlates with immune infiltration in breast cancer. Front Genet. 2022;13:935860. doi: 10.3389/fgene.2022.935860. PMID: 36160004
23. Shi W, Chen Z, Liu H, et al. COL11A1 as an novel biomarker for breast cancer with machine learning and immunohistochemistry validation. Front Immunol. 2022;13:937125. doi: 10.3389/fimmu.2022.937125. PMID: 36389832
24. Liu J, Yang CQ, Chen Q, et al. MiR-4458-loaded gelatin nanospheres target COL11A1 for DDR2/SRC signaling pathway inactivation to suppress the progression of estrogen receptor-positive breast cancer. Biomater Sci. 2022;10(16):4596-4611. doi: 10.1039/d2bm00543c. PMID: 35792605.
25. Hayakawa M, Matsushima M, Hagiwara H, et al. Novel insights into FGD3, a putative GEF for Cdc42, that undergoes SCF(FWD1/beta-TrCP)-mediated proteasomal degradation analogous to that of its homologue FGD1 but regulates cell morphology and motility differently from FGD1. Genes Cells. 2008;13(4):329-42. doi: 10.1111/j.1365-2443.2008.01168.x. PMID: 18363964.
26. Ou Yang TH, Cheng WY, Zheng T, Maurer MA, Anastassiou D. Breast cancer prognostic biomarker using attractor metagenes and the FGD3-SUSD3 metagene. Cancer Epidemiol Biomarkers Prev. 2014;23(12):2850-6. doi: 10.1158/1055-9965.EPI-14-0399. PMID: 25249324.
27. Willis S, Sun Y, Abramovitz M, et al. High Expression of FGD3, a Putative Regulator of Cell Morphology and Motility, Is Prognostic of Favorable Outcome in Multiple Cancers. JCO Precis Oncol. 2017;1:PO.17.00009. doi: 10.1200/PO.17.00009. PMID: 32913979
28. Renda I, Bianchi S, Vezzosi V, et al. Expression of FGD3 gene as prognostic factor in young breast cancer patients. Sci Rep. 2019;9(1):15204. doi: 10.1038/s41598-019-51766-w. PMID: 31645624
29. Susini T, Saccardin G, Renda I, et al. Immunohistochemical Evaluation of FGD3 Expression: A New Strong Prognostic Factor in Invasive Breast Cancer. Cancers (Basel). 2021;13(15):3824. doi: 10.3390/cancers13153824. PMID: 34359725